Environmental, Social And Governance Report

Overview

The report describes Mabpharm's 2024 ESG governance, materiality analysis, climate-risk management and environmental performance. It reports Scope 1 and Scope 2 emissions of 8,940.76 tons and total energy consumption of 21,570.01 MWh. The company had 315 full-time employees, 60.95% of whom were female, and disclosed zero work-related fatalities alongside one work-related injury. The report also highlights product-quality controls, sustainable supply-chain practices and drug-accessibility initiatives.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 26 March 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services